Acer Therapeutics Inc expected to post a loss of 41  cents a share - Earnings Preview

Acer Therapeutics

13/05/2022 12:21

* Acer Therapeutics Inc  ACER.OQ   ACER.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 16
(estimated). 
    * The Newton Massachusetts-based  company is expected to
report  a
37.5% decrease in revenue to $2.5 million from $4 million a year
ago, according to the mean estimate from 2 analysts, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Acer Therapeutics
Inc is
for a loss of 41 cents per share. For the same quarter last
year, the company reported a loss of 11 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acer
Therapeutics
Inc is $10​, above​ its last closing price of $1.83. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.01       -0.01      -0.31     Missed  -3,000
 Sep. 30 2021  -0.28       -0.28      -0.23     Beat    17.9
 Jun. 30 2021  -0.36       -0.36      -0.23     Beat    35.8​
 Mar. 31 2021  -0.44       -0.44      -0.11     Beat    74.9
 ​​Dec.        -0.42       -0.41      -0.50     Missed  -22.7
 31 2020                                                
 Sep. 30 2020  -0.44       -0.46      -0.51     Missed  -10.9​
 Jun. 30 2020  -0.38       -0.38      -0.56     Missed  -48.7
 Mar. 31 2020  -0.42       -0.40      -0.49     Missed  -22.5
 This summary was machine generated May 13 at 11:21 GMT.  All
figures in US dollars  unless otherwise stated